1 / 21

Track B Summary Jeff Lennox Emory University Atlanta

colum
Download Presentation

Track B Summary Jeff Lennox Emory University Atlanta

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Track B Summary Jeff Lennox Emory University Atlanta

    2. Special thanks to my fellow Track B Rapporteurs: Annie Luetkemeyer San Francisco

    3. When to Start ART

    4. When to Start ART

    6. New Drugs and New Strategies

    7. 7 Efficacy and safety of lersivirine vs efavirenz in antiretroviral treatment-naďve HIV-1-infected patients: Week 48 primary analysis results Randomized, double-blind Selection criteria ARV naďve, HIV-1 RNA =1000 c/mL, CD4+ >200 cells/mm3 No RT mutations by standard genotyping Stratified by viral load (<100,000 or =100,000 c/mL) & geographic region (A & B)

    9. Once-daily Dolutegravir, a Next Generation Integrase Inhibitor in in Antiretroviral-naďve Adults 48 Week Results from SPRING-1 (ING112276) Phase IIb dose-ranging, partially-blinded, N~200 ART-naďve patients All arms include 2 NRTI backbone given once daily Primary endpoint: % <50 c/mL at 16 weeks (TLOVR) Planned interim analysis: % <50 c/mL at 48 weeks (TLOVR)

    10. TUAB0102 Van Lunzen DTG: Rapid and Sustained Antiviral Activity Week 48 Efficacy Analysis (%<50 c/mL)

    11. Laboratory Findings > Grade 3 lab abnormalities were rare (DTG 12% vs. EFV 14%) No Grade 3 or 4 ALT elevations in any subject Changes (+/- SD) in serum creatinine over time

    14. Elvitegravir QD is non-inferior to raltegravir BID in treatment experienced patients:48 week results

    15. 2011- The Year of (val)Acyclovir?

    16. Complications

    17.

    18. HIV-Related Predictors and Outcomes in 125 Liver and 150 Kidney Transplant Recipients

    19. Infections

    20. CARINEMO ANRS 12146

    21. 21 Risk factors for TB-IRIS

    22.

More Related